Citigroup Inc Humanigen, Inc Transaction History

Citigroup Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.15 - $3.02 $656 - $13,215	-4,376 Reduced 99.77%	10 $0
Q2 2022 Aug 10, 2022	BUY	$1.76 - $3.33 $1,830 - $3,463	1,040 Added 31.08%	4,386 $8,000
Q1 2022 May 12, 2022	SELL	$1.81 - $3.97 $18,662 - $40,934	-10,311 Reduced 75.5%	3,346 $10,000
Q4 2021 Feb 10, 2022	SELL	$3.66 - $8.22 $997,591 - $2.24 Million	-272,566 Reduced 95.23%	13,657 $51,000
Q3 2021 Nov 10, 2021	BUY	$5.93 - $17.83 $1.7 Million - $5.1 Million	286,223 New	286,223 $1.7 Million

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.